Prelude Therapeutics Incorporated (PRLD)

NMS – Real Time Price. Currency in USD

5.84

+0.52 (9.68%)

Market open: Aug 12, 2026, 11:21 AM EDT

5.36

+0.04 (0.75%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

12M

Cost of goods sold

-2M

-1M

-3M

Gross Profit

10M

-1M

-3M

Operating expenses (excl. COGS)

-115M

-145M

-131M

-120M

Operating Income

-105M

-140M

-132M

-124M

Non-operating income, total

13M

10M

Pretax income

-99M

-127M

-122M

-115M

Equity in earnings

Taxes

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-99M

-127M

-122M

-115M

Discontinued operations

Net income

-99M

-127M

-122M

-115M

Dilution adjustment

Preferred dividends

Prelude Therapeutics Incorporated (PRLD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Prelude Therapeutics Incorporated (PRLD)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Prelude Therapeutics Incorporated (PRLD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Prelude Therapeutics Incorporated (PRLD)

Income Statement (Annual)

Income Statement (Annual)